JP7846211B2 - 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 - Google Patents

治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤

Info

Publication number
JP7846211B2
JP7846211B2 JP2024509302A JP2024509302A JP7846211B2 JP 7846211 B2 JP7846211 B2 JP 7846211B2 JP 2024509302 A JP2024509302 A JP 2024509302A JP 2024509302 A JP2024509302 A JP 2024509302A JP 7846211 B2 JP7846211 B2 JP 7846211B2
Authority
JP
Japan
Prior art keywords
lsd
capsule
formulation according
capsule formulation
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024509302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529728A5 (https=
JP2024529728A (ja
Inventor
マック，ピーター
メルトン，ダスティン
アンバー ドティー，ベサニー
シュローダー，ジョン
コグヒル，ジェームズ
エミール レヴィ，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mind Medicine Inc
Original Assignee
Mind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mind Medicine Inc filed Critical Mind Medicine Inc
Publication of JP2024529728A publication Critical patent/JP2024529728A/ja
Publication of JP2024529728A5 publication Critical patent/JP2024529728A5/ja
Application granted granted Critical
Publication of JP7846211B2 publication Critical patent/JP7846211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024509302A 2021-08-19 2022-08-17 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 Active JP7846211B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163234773P 2021-08-19 2021-08-19
US63/234,773 2021-08-19
PCT/US2022/040653 WO2023023192A1 (en) 2021-08-19 2022-08-17 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Publications (3)

Publication Number Publication Date
JP2024529728A JP2024529728A (ja) 2024-08-08
JP2024529728A5 JP2024529728A5 (https=) 2025-10-10
JP7846211B2 true JP7846211B2 (ja) 2026-04-14

Family

ID=85239753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024509302A Active JP7846211B2 (ja) 2021-08-19 2022-08-17 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
JP2024509301A Pending JP2024529727A (ja) 2021-08-19 2022-08-17 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024509301A Pending JP2024529727A (ja) 2021-08-19 2022-08-17 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤

Country Status (8)

Country Link
US (7) US20230064429A1 (https=)
EP (2) EP4387624A4 (https=)
JP (2) JP7846211B2 (https=)
AU (4) AU2022331315B2 (https=)
CA (2) CA3229017A1 (https=)
IL (2) IL310591A (https=)
TW (3) TWI865366B (https=)
WO (2) WO2023023192A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
JP7846211B2 (ja) * 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN117224540A (zh) * 2023-11-08 2023-12-15 迪沙药业集团有限公司 一种盐酸多奈哌齐的药物组合物
WO2025128594A1 (en) * 2023-12-11 2025-06-19 Mind Medicine, Inc. Methods of treating generalized anxiety disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028942A1 (en) 1997-01-15 2002-03-07 Jacewicz Victor Witold Novel process and compound
US20100203130A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
JP2010531350A (ja) 2007-06-27 2010-09-24 ハンミ ファーム． シーオー．， エルティーディー． 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
US20170258761A1 (en) 2014-08-29 2017-09-14 Sandoz Ag Pharmaceutical Compositions Comprising Canagliflozin
US20200085816A1 (en) 2015-03-10 2020-03-19 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2090430A (en) 1937-08-17 Lysergic acid amides and process for
US2447214A (en) 1948-08-17 Hoocxchoxxchoxxcooh
US1394233A (en) 1921-10-18 Arthur stoll
US3085092A (en) 1963-04-09 Preparation of lysergic acid deriva-
US2774763A (en) 1956-12-18 Preparation of amides of lysergic age
US2265207A (en) 1941-12-09 D-lysergic acid - d - l-bjtdroxybutyl
US2090429A (en) 1937-08-17 Lysergic acid hydkazide and a
US2438259A (en) 1948-03-23 D-lysergic acid diethyl amide
GB579484A (en) 1943-04-30 1946-08-06 Sandoz Ltd Process for the preparation of diethylamide of d-lysergic acid
US2809920A (en) 1953-04-10 1957-10-15 Saul & Co Process for the preparation of ergotamine, ergotaminine and ergometrine by saprophytic culture of ergot (claviceps purpurea [fr] tul.) in vitro and isolation of the alkaloids thus produced
US2796419A (en) 1954-09-27 1957-06-18 Lilly Co Eli Lysergic acid, intermediates and preparation
US2736728A (en) 1954-12-06 1956-02-28 Lilly Co Eli Preparation of lysergic acid amides
US2997470A (en) 1956-03-05 1961-08-22 Lilly Co Eli Lysergic acid amides
US3038840A (en) 1959-07-07 1962-06-12 Farmaceutici Italia Process for the production of alkaloid derivatives of lysergic acid
FR1338023A (fr) 1962-10-15 1963-09-20 Farmaceutici Italia Nouveau procédé de préparation d'amides d'acide lysergique, substituées ou non
US3239530A (en) 1964-01-13 1966-03-08 Sandoz Ltd Process for lysergic acid hydrazides
CH535236A (de) 1970-06-19 1973-03-31 Sandoz Ag Verfahren zur Herstellung neuer reaktionsträger Lysergsäurederivate
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
CA2134611C (en) 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms
US6063908A (en) 1996-07-02 2000-05-16 Roche Diagnostics Corporation Reagents for lysergic acid diethylamide immunoassay
CA2347469C (en) 1998-10-14 2006-02-28 Aventis Pharmaceuticals Inc. Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
US6794496B2 (en) 2000-04-07 2004-09-21 Roche Diagnostics Corporation Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
AU2002237548B2 (en) * 2001-03-06 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
ATE496917T1 (de) 2001-12-20 2011-02-15 Randox Lab Ltd Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115473A2 (en) * 2004-05-24 2005-12-08 Nutrinia Ltd. Nutritional food and feed, composition, processing and method of use
ES2651021T3 (es) 2004-07-24 2018-01-23 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecánica
US20060039890A1 (en) 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
JP2006124282A (ja) 2004-10-26 2006-05-18 Central Glass Co Ltd ３，３，３−トリフルオロプロピオン酸の製造方法
US20060167481A1 (en) 2005-01-25 2006-07-27 Esophyx, Inc. Slitted tissue fixation devices and assemblies for deploying the same
US20060223998A1 (en) 2005-03-30 2006-10-05 Fang-Jie Zhang Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CN101460150B (zh) * 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN101932577B (zh) 2007-11-30 2013-07-17 拜耳知识产权有限责任公司 杂芳基取代的哌啶
US9642819B2 (en) 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
JP5690732B2 (ja) * 2008-09-17 2015-03-25 ザ マクリーン ホスピタル コーポレーション 群発頭痛障害を治療するための方法及びキット
US10548839B2 (en) * 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
CA2816551A1 (en) 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
WO2014059197A1 (en) 2012-10-10 2014-04-17 Henkin Robert I Methods and compositions for diagnosing and treating hyposmia
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
CN113616883B (zh) 2014-06-30 2023-06-06 Syqe医药有限公司 向受试者肺部递送植物材料中的至少一药理活性剂的系统
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
CN107206093A (zh) 2015-01-28 2017-09-26 韩国真耐瑞斯有限公司 用于治疗神经精神类障碍的组合物及方法
WO2016168891A1 (en) 2015-04-18 2016-10-27 Baycrest Technology Pty Ltd Medication dosing report
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
WO2017066488A1 (en) 2015-10-13 2017-04-20 Charleston Laboratories, Inc. Treating pain using a composition comprising an opioid and an antiemetic
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US20200222656A1 (en) 2016-10-18 2020-07-16 Joseph Rustick Method for treatment of depression using synaptic pathway training
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
NZ757591A (en) 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
JP2021500948A (ja) 2017-10-19 2021-01-14 エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド サイケデリック薬剤療法の安全性を向上させる方法およびシステム
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
CA3081626A1 (en) 2017-11-07 2019-05-16 MedReleaf Corp. Dosage and varietal recommendations for the treatment of medical conditions using cannabis
US11367103B2 (en) 2020-03-02 2022-06-21 Yieldmo, Inc. Method for modeling digital advertisement consumption
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
WO2020024977A1 (zh) 2018-08-01 2020-02-06 陕西麦科奥特科技有限公司 用于治疗神经系统疾病的化合物及其应用
MA54877A (fr) 2019-01-30 2021-12-08 Diamond Therapeutics Inc Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP2022530390A (ja) 2019-04-24 2022-06-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗精神病剤の応答を予測するための方法
AU2020274186A1 (en) 2019-05-14 2021-12-09 The Scripps Research Institute Compounds for the treatment of neurodegenerative and metabolic disorders
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
GB201911024D0 (en) 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
BR112022002723A2 (pt) 2019-08-13 2022-07-19 Univ Maryland Métodos de tratamento de transtornos psicológicos e do cérebro
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
JP2023515616A (ja) 2020-02-28 2023-04-13 ユニヴェルシテートスピタル バーゼル ５ｈｔ２ａアゴニストの投与後の抑制効果
GB202003059D0 (en) 2020-03-03 2020-04-15 Beckley Found Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
CA3175211A1 (en) 2020-04-13 2021-10-21 Matthias Emanuel LIECHTI Lsd dose identification
MX2022012537A (es) 2020-04-16 2022-11-07 Pike Therapeutics Inc Entrega transdermica de microdosis de derivados psicodelicos.
US20230210762A1 (en) 2020-05-01 2023-07-06 Emergex USA Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021225796A1 (en) 2020-05-05 2021-11-11 Universitätsspital Basel Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
WO2021243461A1 (en) 2020-06-04 2021-12-09 Neonmind Biosciences Inc. Use of lsd, esa, or dmt for weight loss.
BR112022025317A2 (pt) 2020-06-15 2023-01-03 Univ Basel Método de dosagem de um empatógeno/entactógeno no tratamento de pacientes; método para determinar uma dose de um empatógeno/entactógeno com base no peso corporal, sexo e atividade de cyp2d6; método para refinar a dosagem de um empatógeno/entactógeno; método para predizer a dosagem futura com um empatógeno/entactógeno; método para avaliar a viabilidade de pacientes para receber um empatógeno/entactógeno como tratamento; e método para otimizar o tratamento com empatógeno/entactógeno em um paciente
EP4167992A1 (en) 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
US20210407643A1 (en) 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
US20230286975A1 (en) 2020-07-07 2023-09-14 Compass Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
EP4188382A4 (en) 2020-07-29 2024-08-14 The Royal Institution for the Advancement of Learning / McGill University Administration of modulators of 5-ht and/or ampa receptors for treating neurological conditions
WO2022023812A1 (en) 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Extended release 5-ht receptor agonists for neurological conditions
JP7584066B2 (ja) 2020-08-06 2024-11-15 株式会社一志精工電機 金型構造、プレス加工装置、およびプレス加工方法
DE202020105085U1 (de) 2020-09-03 2020-11-30 Sophie-Charlotte Adler Therapiemethode in Kombination mit psychoaktiver Zusammensetzung
CN116391128B (zh) 2020-10-24 2025-11-21 巴塞尔大学医院 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法
WO2022107095A1 (en) 2020-11-22 2022-05-27 Havn Life Sciences Inc. Methods and compositions for treating pain with 2-bromo-lysergic acid diethylamide and thymoquinone
WO2022115796A1 (en) 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating neurological conditions
CA3203642A1 (en) 2020-12-02 2022-06-09 The Johns Hopkins University Restoration of motor function post-neurological injury using psychedelics
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
EP4301464A1 (en) 2021-03-06 2024-01-10 Universitätsspital Basel Using geno- or phenotyping to adjust lsd dosing
CA3215871A1 (en) 2021-03-31 2022-10-06 Lyfe Chng, Llc Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent
WO2022221942A1 (en) 2021-04-19 2022-10-27 Betterlife Pharma Inc. Prevention of drug diversion
US20230116703A1 (en) 2021-04-23 2023-04-13 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
US20240368151A1 (en) 2021-04-23 2024-11-07 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
JP2024517194A (ja) 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
US20220362237A1 (en) 2021-05-03 2022-11-17 Mind Medicine, Inc. Psychedelics for treatment of pain
WO2022235500A1 (en) 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
US20230301985A1 (en) 2021-05-04 2023-09-28 Mind Medicine, Inc. Movement disorders
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
BR112023024688A2 (pt) * 2021-05-26 2024-02-15 Mindset Pharma Inc Combinação de halucinógeno-ácido graxo
WO2022261058A1 (en) 2021-06-07 2022-12-15 University Of Mississippi Methods for the pulsed delivery of bioactive agents
WO2022265878A1 (en) 2021-06-14 2022-12-22 Mind Medicine, Inc. Controlling effects after 5ht2a agonists administration
EP4366729A4 (en) 2021-07-07 2025-06-11 Arcadia Medicine, Inc. SAFER PSYCHOACTIVE COMPOSITIONS
WO2023012691A1 (en) 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
WO2023012524A2 (en) 2021-08-03 2023-02-09 Universitatsspital Basel Lsd and psilocybin dose equivalence determination
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
WO2023043870A1 (en) 2021-09-15 2023-03-23 Eleusis Therapeutics Us, Inc. Chewing gum formulation of lsd and methods of use thereof
KR20240088949A (ko) 2021-09-20 2024-06-20 비라이프 테라퓨틱스 인크. 질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법
WO2023107966A1 (en) 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
WO2023108277A1 (en) 2021-12-14 2023-06-22 Agile Pharmaceuticals Solutions Inc. Cannabinoid and psychedelic formulations comprising hydrotropic agents
US20250109130A1 (en) 2021-12-16 2025-04-03 Terran Biosciences Inc. Isotopically enriched analogs of 2-bromo-lsd, lsd, ald-52, and 1p-lsd
WO2023114529A2 (en) 2021-12-17 2023-06-22 Bennes, Inc. Pharmacoactive formulations for delivery of psychedelic compounds
WO2023183618A1 (en) 2022-03-25 2023-09-28 Ojai Energetics Pbc Psychedelic compositions and methods for forming the same
US20250295611A1 (en) 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
US20230346645A1 (en) 2022-05-01 2023-11-02 Mind Medicine, Inc. Method of titrating dose of psychedelics
JP2025525375A (ja) 2022-06-20 2025-08-05 マインド メディシン， インコーポレイテッド 修飾ｌｓｄ様作用を有するリゼルグ酸誘導体
US20260034058A1 (en) 2022-08-09 2026-02-05 Vitalmelt Ltd. Freeze-dried bite with single dose psychedelic
WO2024229454A2 (en) 2023-05-04 2024-11-07 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
WO2024238035A1 (en) 2023-05-16 2024-11-21 Mind Medicine, Inc. Movement disorders
US20250312309A1 (en) 2023-06-22 2025-10-09 Mind Medicine, Inc. Allyl-and propargylamine-type phenethylamines and tryptamines for treating medical disorders
WO2025128594A1 (en) 2023-12-11 2025-06-19 Mind Medicine, Inc. Methods of treating generalized anxiety disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028942A1 (en) 1997-01-15 2002-03-07 Jacewicz Victor Witold Novel process and compound
JP2010531350A (ja) 2007-06-27 2010-09-24 ハンミ ファーム． シーオー．， エルティーディー． 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
US20100203130A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
US20170258761A1 (en) 2014-08-29 2017-09-14 Sandoz Ag Pharmaceutical Compositions Comprising Canagliflozin
US20200085816A1 (en) 2015-03-10 2020-03-19 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
TWI865366B (zh) 2024-12-01
US20230064429A1 (en) 2023-03-02
EP4387623A4 (en) 2025-07-02
US20230285386A1 (en) 2023-09-14
WO2023023182A1 (en) 2023-02-23
AU2022331315A1 (en) 2024-02-22
CA3229017A1 (en) 2023-02-23
JP2024529728A (ja) 2024-08-08
AU2022331317A1 (en) 2024-02-29
AU2022331317B2 (en) 2025-09-11
US12036220B2 (en) 2024-07-16
WO2023023192A1 (en) 2023-02-23
US20230122949A1 (en) 2023-04-20
EP4387624A4 (en) 2025-07-30
AU2026200219A1 (en) 2026-01-29
JP2024529727A (ja) 2024-08-08
TWI838826B (zh) 2024-04-11
TW202317116A (zh) 2023-05-01
US12521385B2 (en) 2026-01-13
EP4387624A1 (en) 2024-06-26
US12527786B2 (en) 2026-01-20
TW202434244A (zh) 2024-09-01
IL310569A (en) 2024-03-01
CA3228975A1 (en) 2023-02-23
US20250345323A1 (en) 2025-11-13
US20230075847A1 (en) 2023-03-09
TW202315627A (zh) 2023-04-16
EP4387623A1 (en) 2024-06-26
US20230107398A1 (en) 2023-04-06
US20230218532A1 (en) 2023-07-13
AU2022331315B2 (en) 2025-10-16
AU2025275308A1 (en) 2026-01-15
IL310591A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
JP7846211B2 (ja) 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
CA2683436C (en) Melatonin tablet and methods of preparation and use
JP2022084651A (ja) 新規組成物および方法
CA3097053C (en) Edaravone pharmaceutical composition
US12128027B2 (en) N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof
CN114716417B (zh) 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
JPWO2007049626A1 (ja) カベルゴリン含有経口固形製剤
CN121360090A (zh) 一种孟鲁司特钠咀嚼片及其制备方法和应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260402

R150 Certificate of patent or registration of utility model

Ref document number: 7846211

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150